MSB 7.69% $1.19 mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-567

  1. 5,631 Posts.
    lightbulb Created with Sketch. 2034
    Failed Stem Cell 101?

    I know this has been posted a dozen times, but apparently some people still don't get it:


    https://www.globenewswire.com/news-release/2020/09/15/2093510/0/en/Mesoblast-Wins-2020-Fierce-Biotech-Innovation-of-the-Year-Award-for-remestemcel-L.html

    Mesoblast Wins 2020 Fierce Biotech Innovation of the Year Award for remestemcel-L

    About Fierce Innovation Awards – Life Sciences Edition 2020
    These awards highlight companies that demonstrate innovative solutions, technologies, and services that have the potential to make the greatest impact for biotech and pharma companies. The evaluation criteria are effectiveness, technical innovation, competitive advantage, financial impact, and true innovation. The awards program’s applications were reviewed by a panel of executives from major biotech and pharma companies including Astellas, Accenture, AstraZeneca, Angiocrine Bioscience, Biotech Research Group, NIHR Clinical Research Network, Medidata Solutions and PPD.

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.19
Change
0.085(7.69%)
Mkt cap ! $1.358B
Open High Low Value Volume
$1.10 $1.20 $1.09 $13.21M 11.37M

Buyers (Bids)

No. Vol. Price($)
1 15000 $1.19
 

Sellers (Offers)

Price($) Vol. No.
$1.19 75212 5
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.